$599

BI Survo GLP-1 Use Update; Ionis Q3 ’26 Earnings; Lilly ATTAIN-OSA Data; November CHMP Agenda

A series of cardiometabolic-related news items has been observed from Boehringer Ingelheim, Ionis, Lilly, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here